Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed/refractory multiple myelomaSuzette Girgis, Jenna D. Goldberg, Arnob Banerjee et al.|Blood Advances|2022Cited by 52
Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Correlative Analyses from MajesTEC-1Diana Cortés‐Selva, Raluca Verona, Tineke Casneuf et al.|Blood|2022Cited by 46
P32 MAJESTEC-1: CORRELATIVE ANALYSES OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN (BCMA) X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)Niels W.C.J. van de Donk, Raluca Verona, Diana Cortés‐Selva et al.|HemaSphere|2023Cited by 7
Teclistamab and talquetamab modulate levels of soluble B-cell maturation antigen in patients with relapsed and/or refractory multiple myeloma.Suzette Girgis, Jenna D. Goldberg, Shun Xin Wang Lin et al.|Journal of Clinical Oncology|2021Cited by 5
P-001: Modulation of soluble B-cell maturation antigen levels in patients with relapsed and/or refractory multiple myeloma after treatment with teclistamab and talquetamabSuzette Girgis, Jenna D. Goldberg, Shun Xin Wang Lin et al.|Clinical Lymphoma Myeloma & Leukemia|2021Cited by 1